Next Article in Journal
NGS-Based Genetic Analysis in a Cohort of Italian Patients with Suspected Inherited Myopathies and/or HyperCKemia
Previous Article in Journal
The Current State of Charcot–Marie–Tooth Disease Treatment
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Genes
Volume 14
Issue 7
10.3390/genes14071392
genes-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

ADH1B, ADH1B/C and CYP2E1 Gene Polymorphism and the Risk of Fetal Alcohol Spectrum Disorder

by
Arnold Kukowka
1,*,
Bogusław Brzuchalski
1,
Mateusz Kurzawski
2,
Damian Malinowski
1 and
Monika Anna Białecka
1
1
Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, Aleja Powstanców Wielkopolskich 72 St., 70-111 Szczecin, Poland
2
Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, Aleja Powstanców Wielkopolskich 72 St., 70-111 Szczecin, Poland
*
Author to whom correspondence should be addressed.
Genes 2023, 14(7), 1392; https://doi.org/10.3390/genes14071392
Submission received: 31 May 2023 / Revised: 24 June 2023 / Accepted: 27 June 2023 / Published: 2 July 2023
(This article belongs to the Section Human Genomics and Genetic Diseases)
Versions Notes

Abstract

:
Increasing alcohol consumption by women of childbearing age contributes to more frequent cases of fetal alcohol spectrum disorder. The cause of the syndrome is fetal alcohol exposure, particularly what is referred to as high prenatal alcohol exposure. Low metabolic activity of fetal enzymes shifts the burden of ethanol removal to maternal metabolism. One of the factors influencing the pathogenesis of FASD is the genetic background. It can determine the rate of elimination of ethanol, thus increasing or decreasing the time of fetal exposure to ethanol and also decreasing its concentration. Genetic polymorphisms could potentially play a significant role in these processes. In the present study, we considered three polymorphisms of genes implicated in the synthesis of enzymes involved in ethanol metabolism, i.e., ADH1b (rs1229984), ADH1b/c (rs1789891), and CYP2E1 (rs3813867). The studied group consisted of 303 children and 251 mothers. Both mothers’ and children’s genotypes were considered in our analysis. There were no statistically significant differences between the respective groups of genotypes of the studied polymorphisms. However, the genetic background of FASD is still elusive.
Keywords:
FASD; alcohol; SNP

1. Introduction

With the knowledge of the human genome, the opportunity has come to better understand the influence of genotype on phenotype in the context of central nervous system disorders. Single nucleotide polymorphisms (SNPs) were of particular interest to the researchers [1]. In diseases of multifactorial pathogenesis, such as epilepsy, schizophrenia, depression, or autism, knowledge of SNPs provides an opportunity to better understand the cause of the disease and to design more effective pharmacotherapy [2]. One of the disorders whose phenotypic presentation may be influenced by a genetic factor is fetal alcohol spectrum disorder (FASD) [3,4]. By definition, FASD includes fetal alcohol syndrome (FAS) and partial fetal alcohol syndrome (p-FAS), as well as alcohol-related birth defects (ARBD), alcohol-related neurodevelopmental disorders (ARND), and neurobehavioral disorders associated with prenatal alcohol exposure (ND-PAE) [5]. Epidemiologically, it is estimated that about 10% of pregnancies have prenatal alcohol exposure (PAE)—resulting in 77 children diagnosed with FASD and about 15 with the most severe form of FAS (fetal alcohol syndrome) for every 1000 newborns [6,7]. All developing fetal systems are susceptible to the harmful effects of ethyl alcohol [8], but the nervous system is the most vulnerable. It is primarily damaged by increased oxidative stress and harmful ethanol metabolites [9,10]. The alcohol toxicity results in a very extensive symptomatology of FASD, including symptoms such as dysmorphologies (e.g., short palpebral fissure, smooth philtrum, or thin upper lip), neuropsychological and sensory disorders, as well as neurological symptoms, including epilepsy [11,12].
Fetal exposure to alcohol is the only necessary condition for the development of FASD. However, not every fetus exposed to alcohol will later develop FASD—studies estimate that 10% to 15% of children exposed as fetuses to alcohol will suffer from FASD [13]. This is due to numerous other risk factors. Among these, we can distinguish three main groups of risk factors. Those dependent on the mother (e.g., mother’s age), those dependent on agent exposure (e.g., binge drinking or drinking outside of meals), and those dependent on the environment (e.g., little knowledge of FASD) [14]. Their role and the genetic influence are associated with the degree of risk for disorders on the spectrum of fetal alcohol disorders and their severity [3,15,16]. The variety of risk factors and the individual susceptibility to develop FASD prompt further research including genetic research. Individual susceptibility to alcohol toxicity, and thus the development of FASD, may be related to genetic determinants [3,17,18]. Particularly important is the activity of enzymes responsible for alcohol metabolism in both mothers and fetuses with h-PAE (high prenatal alcohol exposure) [17]. Two pathways of alcohol metabolism are distinguished: oxidative—involving alcohol dehydrogenase (ADH), aldehyde dehydrogenase (ALDH), catalase, and the P450 cytochrome (mainly CYP2E1)—and non-oxidative [18,19,20]. Both lead to the synthesis of products that are toxic [21]. For example, increased susceptibility to alcohol toxicity in the prenatal period may be associated with maternal genetic variants that determine the activity of enzymes involved in alcohol metabolism since they play a dominant role in the elimination of alcohol [3,13,17,18,22]. We distinguish three main genes that encode the activity of alcohol dehydrogenase (ADH)—ADH1A, ADH1B, and ADH1C [23]. The translation of these genes produces corresponding polypeptides, which are the subunits of the alcohol dehydrogenase isoenzymes. The translation product of the ADH1B gene is the β subunit [24]. One of the most studied polymorphisms of the ADH1B gene is ADH1B*2 (rs1229984). In the carriers, arginine at position 48 is converted to histidine (Arg48His) resulting in altered enzyme activity and alcohol metabolism [19]. Yin et al. found in an in vitro study that the maximum rate of oxidation of ethanol to acetaldehyde is about 100 times higher in carriers of the A allele. These individuals have β2 subunits that are components of aldehyde dehydrogenase isoenzymes [25]. Carriers of one or two A alleles have increased enzymatic activity of alcohol dehydrogenase—thus, the negative effects of alcohol consumption are present more quickly, which is associated with a lower risk of alcohol dependence [26,27,28]. Another less investigated SNP is rs1789891. It is located on the long arm of chromosome 4 between the ADH1B and ADH1C genes [29]. The role of this polymorphism is yet to be fully understood, but it is in total linkage disequilibrium with another polymorphism, rs1693482 in the ADH1C gene [29,30]. Rs1693482 results in a functional change, i.e., substitution of glutamine for arginine at position 272. People with the arginine variant at position 272 (C allele, 272Arg) metabolize ethyl alcohol twice as fast, and the enzyme itself has twice the affinity for ethanol compared to 272Gln (T allele, 272Gln) [31,32]. As shown in the study by Osier et al., the C allele is associated with a lower risk of alcoholism in the Asian population [33], which has also been confirmed in other studies with regard to this population [34,35]. A slower metabolism of ethyl alcohol was associated with the T allele. A lower concentration of toxic metabolites translates into better tolerance of ethyl alcohol, its higher consumption, and a potentially higher risk of developing addiction [30,31]. As mentioned above, the rs1693482 polymorphism remains in linkage disequilibrium with the rs1789891 polymorphism, i.e., the C allele of the ADH1B/1C rs1789891 gene is correlated with the C allele of rs1693482. The same is true for the T allele of the polymorphism that we studied (rs1789891). Therefore, people who carry the C allele of the rs1789891 polymorphism metabolize alcohol faster, in contrast to people who carry the A allele (rs1789891) [31,36]. The role of rs1789891 is inconclusive. There are studies that do not support the association between rs1789891 and the risk of alcohol dependence [37], while other authors point to an association between carrying the A allele of this polymorphism and a greater risk of alcohol dependence [30].
The third SNP of interest is rs3813867 of the CYP2E1 gene. The CYP2E1 enzyme encoded by this gene belongs to the group of CYP450 enzymes that are responsible for the metabolism of numerous xenobiotics, including drugs and ethyl alcohol [20,38]. In this polymorphism, guanine (C1 allele) is converted to cytosine (C2 allele) at position 1259 of the long arm of chromosome 10. The C2 allele corresponds to cytosine, while the C1 allele is bound to guanine [39,40]. The transcriptional activity of the CYP2E1 gene is increased 10-fold in carriers of the C2 allele [41]. It is also important to note that chronic alcohol consumption is an inducer of CYP2E1 enzyme activity, which can lead to the synthesis of toxic metabolites [42]. CYP2E1 also generates free radicals when ethanol is metabolized [41,43]. Regarding ethanol, studies suggest that carrying the C2 allele is associated with increased alcohol consumption [44]. Researchers also suggest that CYP2E1 polymorphisms may play a role in the pathogenesis of FASD [45,46]. The newborn’s ability to eliminate alcohol averages 83.5% of the mother’s rate. Many studies have reported cases in which the blood alcohol content (BAC) of the newborn after birth was higher than the BAC of the mother. This can be explained not only by the lower ability of the fetus to eliminate alcohol but also by the phenomenon of the constant intake of amniotic fluid, which accumulates alcohol excreted by the fetus in unchanged form (due to low metabolic efficiency) [17]. The estimated efficiency of alcohol metabolism by the fetal liver is about 5–10% (of that reported in adults) in the early stages of development, mainly due to alcohol dehydrogenase, which is detected around the 8th week of pregnancy [47,48]. The ability of the fetal liver to metabolize alcohol increases with the duration of pregnancy, reaching a maximum of 50% of the maternal liver capacity [49]. On the other hand, the activity of CYP2E1 enzyme can be detected around the 19th week of pregnancy [50]. However, its activity is much lower than in adults [51,52]. The limited activity of ADH and CYP3A4 increases the toxicity of alcohol and its harmful metabolites, which may be further influenced by both the way the mother drinks and the mother’s and fetus’s genetically determined ability to metabolize ethyl alcohol [10]. The aim of this study is to answer the question of whether the SNPs of the ADH1B, ADH1B/1C, or CYP2E1 genes in drinking mothers and children exposed to h-PAE have an impact on the risk of FASD and the degree of severity of FASD morphological features in the population of Polish children.

2. Materials and Methods

Throughout this paper, children with FAS are referred to as the FC group (FAS children) and other groups are referred to as children with pFAS—PFC (partial FAS children), or children without FAS—NFC (non-FAS children). Children in the number of 303 (213 girls, mean age 8.59 ± 4.77 years; 90 boys, mean age 9.77 ± 5.14 years) and 251 mothers (mean age 32.80 ± 5.92 years) were included in this study. The study group consisted of 303 children with hPAE, of whom 183 were diagnosed with FASD (partial FAS children—PFC, n = 42:37 girls, mean age 8.32 ± 3.92 years; 5 boys, mean age 10.60 ± 3.13 years, and FAS children—FC, n = 141:84 girls, mean age 8.43 ± 5.39 years; 57 boys, mean age 9.75 ± 4.48 years) and NFC children without the presence of obvious morphological FAS changes, unless there was a positive history of hPAE (non-morphological FAS children—NFC, n = 120:92 girls, mean age 8.58 ± 4.51 years; 28 boys, mean age 9.64 ± 6.62 years). The mother’s study group consisted of 251 women, mean age 32.77 ± 5.93, with confirmed alcohol consumption during pregnancy. Mothers were divided into subgroups accordingly to their children’s hPAE status. The demographics of the study group are summarized in Table 1.
All the children enrolled in this study met the criteria for the occurrence of high levels of alcohol exposure during fetal life. PAE was confirmed by the mother’s medical history or by an objectively documented background investigation (e.g., mother’s stay in a sobering center or detoxification unit during pregnancy). Detailed information regarding FASD and ADHD diagnosis enclosed in supplementary materials. The criteria for excluding children from this study were psychiatric disorders including significant mood and anxiety disorders requiring pharmacological treatment, psychotic disorders (current and history), risky and harmful use of psychoactive substances (SPAs) (current and history) or addiction to SPAs, and developmental disorders including autism spectrum disorder, profound and significant mental retardation, genetic diseases, severe and uncompensated somatic diseases (endocrinological, cardiovascular, renal, neoplastic, autoimmune, anorexia), and organic diseases with clinical manifestations (epilepsy), slight underweight and low height for age but within normal limits (>10th centile). A history of depressive episodes and emotional and behavioral disorders did not exclude patients from this study.

2.1. Genetic Analysis

Genomic DNA was extracted from buccal swabs. Cells from the mucosal membrane were collected using a sterile synthetic swab. Prior to isolation, swabs were stored in a preservative buffer at +4 °C. DNA extraction was performed using the Genomic Micro AX SWAB Gravity Kit (A&A Biotechnology, Gdynia, Poland) according to the manufacturer’s protocol. Subsequently, based on spectrophotometric absorbance measurement (260/280 nm), the DNA was standardized to equal concentrations of 10 ng/µL. Genotyping for the following single nucleotide polymorphisms (SNPs), ADH1B rs1229984, rs1789891, CYP2E1 rs3813867, was performed using prevalidated allelic discrimination TaqMan real-time PCR assays (TaqMan Assay ID’s: C___2688467_20, C___8829540_10, C___2431875_10, Life Technologies, Waltham, MA, USA) and TaqMan GTXpress Master Mix (Life Technologies, Waltham, MA, USA). All reactions were performed in duplicate in a final volume of 12 µL (reaction temperature profile: 95 °C, 20 s; 40 × 95 °C 1 s/60 °C, 20 s). Fluorescence data were measured using the ViiA7 Real-Time PCR System (Applied Biosystems, Waltham, MA, USA) after a 40-cycle reaction. Genotypes were assigned to individual samples after analysis using the TaqMan Genotyper software (Thermo Fisher Scientific, Waltham, MA, USA). Alleles correlated with extensive alcohol metabolism and presumably connected with high acetaldehyde production were considered as risk alleles in multivariate analysis.

2.2. Statistical Analysis

The χ2-Pearson test (chi2) and/or Fisher’s exact test were used to compare qualitative variables between the genotype groups, alleles, and data within genotype groups. Hardy–Weinberg equilibrium was calculated for genotype and allele distribution frequencies in each study group. Student’s t-test was used to calculate SNPs additive level. p value < 0.05 was considered statistically significant. Statistical analysis was performed using STATISTICA PL, ver. 13.1, software (StatSoft, Inc. 2016, Tulsa, OK, USA).

3. Results

The group of 303 children was divided into three subgroups: FAS children (FC), pFAS children (PFC), and non-FASD children (NFC). Mothers were divided into three groups: mothers of FAS children (FC mothers), mothers of pFAS children (PFC mothers), and mothers of non-FASD children (NFC mothers). The discrepancy in the number of mothers is due to the fact that some of the mothers who participated in this study were mothers of multiple children. Mothers were also counted for each group (FC, PFC, NFC). For example, a mother with three children with pFAS alone is counted as one. Conversely, mothers with both FAS and non-FASD children were counted as FC and NFC mothers. First, the frequency of genotypes in mothers and children was compared separately for FAS and pFAS and no statistically significant differences were found against non-FAS (Supplementary Tables S1–S4). Then, in order to increase the statistical power of the conducted analysis, the FAS and pFAS groups were combined and again compared with non-FAS mothers (Table 2) and children (Table 3). The analysis conducted showed no differences in the frequency of genotypes. For all the analyses shown in Table 2 and Table 3, and the Supplementary Tables, the genotype distribution was in concordance with Hardy–Weinberg Equilibrium (HWE, p > 0.05). Moreover, the results of our study did not confirm that the infants are more likely to develop FASD if their and their mothers’ genotypes have a specific combination for an additive effect (Supplementary Table S5).

4. Discussion

This study examined the association between the polymorphisms of the genes encoding ADH and CYP3A4 and the risk of FASD in children exposed to ethanol in the prenatal period. There was no association between the polymorphisms of the genes ADH1b (rs1229984), ADH1B/1C (rs1789891), and CYP2E1 (rs3813867) and the risk of FASD.

4.1. ADH1B

The first of the studied polymorphisms of the ADH1B gene (rs1229984) has been evaluated in the context of the pathogenesis of alcohol use disorder (AUD). Genetic variation within the ADH1B gene determines the rate at which ethanol is metabolized to acetaldehyde [53,54]. The conversion of Arg48 to His48 is the effect of substituting adenine (A) for guanine (G). Two alleles are therefore distinguished: the allele (G) encoding arginine at position 48, which is considered the most common allele, and the allele (A) encoding histidine at position 48, which is more common in East Asian populations [19,26,53,54]. This change (Arg48His) leads to an approximately 40-fold increase in the enzymatic activity of alcohol dehydrogenase, and, as a result, the negative effects of alcohol consumption—for example, nausea or abdominal pain—are felt more quickly [19]. Thomasson et al. showed significant differences in the frequency of genotypes and the A allele of the rs1229984 between addicts and non-alcoholics. In the former, the A allele occurred much less frequently. In accordance with this, individuals who were homozygous for the AA genotype were less likely to meet the DSM-3 criteria for alcohol dependence compared to individuals who were heterozygous for the GA genotype or homozygous for the GG genotype [55]. The protective role of the A rs1229984 allele in relation to alcohol dependence was further supported by the work of Thomasson et al. and many other studies [26,27,56,57,58,59].
Less is known about the impact of the ADH1B gene SNP (rs1229984) in the development of FASD. In 2001, a study by Viljoen et al. showed a lower incidence of the A allele in mothers and their children with FAS. The study was conducted on 56 mother–child pairs with FAS. A possible explanation for this phenomenon is the protective role of this allele, which is associated with faster metabolism of ethanol to acetic aldehyde, resulting in the aforesaid increased symptoms of alcohol intolerance and thus less propensity to consume alcohol [60].
The protective effect of the A allele of the ADH1B (rs1229984) gene in the context of FASD appears plausible. Its carriers metabolize alcohol faster, which determines the lower exposure of the fetus to its harmful effects. In addition, a lower risk of addiction in the carriers may prevent alcohol dependence and thus indirectly protect the child from fetal exposure to alcohol. In addition, Zuccolo et al. showed that mothers with the A allele drank less alcohol during pregnancy, were less likely to binge-drink, and were more likely to quit drinking during pregnancy. Indirectly, this indicates the potential protective role of the allele by reducing the propensity of the mother to drink alcohol during pregnancy [30,61].
However, the results of the current study showed no protective effect of the ADH1B polymorphism (rs1229984) on the risk of FAS or pFAS (Table 2 and Table 3). In the case of children, the analysis of genotypes did not show any association between PFC + FC vs. NFC (p = 0.436). We obtained a comparable outcome for the mothers’ genotypes (p = 0.438). No significant results were also seen for individual analysis of FC vs. NFC, PFC vs. NFC—in both mothers and children’s groups (Supplementary Tables S1–S4). One of the limitations of the current study is a very low frequency of ADH1B variant alleles and genotypes in both mother’s and children’s groups (A allele frequency <5%, which resulted in only 1 AA homozygote among mothers, and the absence of AA homozygotes in children). That fact makes it difficult to reliably assess the effect of the rs1229984 SNP. Similarly, in other studies on European populations or of populations of European descent (e.g., Australian), the low frequency of this polymorphism is pointed out as a significant obstacle in assessing its role in FASD pathology [30,53,57].

4.2. ADH1B/1C

The second genetic polymorphism tested was SNP rs1789891 located in the ADH1B/1C gene cluster. As already mentioned, this is a polymorphism that is in complete linkage with the SNP of the ADH1C rs1693482 gene [29,30]. The rs1789891 polymorphism studied in this paper is characterized by the presence of the C allele, which is considered to be potentially protective against alcohol dependence, and the A allele, which exerts no such effect [31,36]. The choice of that polymorphism resulted from its still unexplained role in the development of FASD, despite attempts to assess its importance in predisposing to alcohol dependence. Bach et al. showed that carrying the A allele is associated with a higher risk of relapse to ethyl alcohol dependence, and that A allele carriers consume more of it than people with the homozygous CC genotype [36]. In addition, the same study demonstrated reduced gray matter loss in the CC homozygotes [36]. This may indicate an indirect neuroprotective effect of this allele, and thus, in the context of alcohol exposure in fetal life, may protect the nervous system of the developing fetus. The GWAS study by Frank et al. also suggests a protective role of the C allele in the context of alcohol dependence [27]. Similar results were found by Way et al. [28].
Despite the potential importance of the polymorphism, such studies have not yet been conducted on a group of children exposed to high levels of alcohol during their fetal period. The results of the current research revealed no association between rs1789891 and FASD risk. Mothers’ genotype did not impact the risk of FAS/pFAS (p = 0.587) and neither did the children’s genotype (p = 0.954) (Table 2 and Table 3). Individual genotype comparisons for FC vs. NFC and PFC vs. NFC did not show statistically important results (Supplementary Tables S1–S4). The frequency of the rs1789891 alleles and genotypes was similar in all study groups, with the CC genotype being the most common. As the SNP does not directly affect enzymatic activity, and the linkage varies among populations, it is hard to predict the effect of the SNP on alcohol metabolism in the study subjects. Hence, it is difficult to identify the cause of the negative results of the SNP association with the risk of FASD. In the population under study, the rs1789891 SNP did not appear to play a significant role in the risk of fetal alcohol syndrome in children exposed to hPA, even though the C allele was previously pointed out as potentially protective against alcohol dependence. In future research, other ADH1 variants may be investigated, including the aforementioned rs1693482 polymorphism of the ADH1C gene.

4.3. CYP2E1

CYP2E1 is a major component of the P-450 cytochrome, which plays an important role in the metabolism of ethyl alcohol [62]. The activity of CYP2E1 is genetically determined, which is important because CYP2E1 activity tends to increase in people who abuse alcohol [63]. Therefore, the last polymorphism we studied was the SNP of the cytochrome P-450 2E1 (CYP2E1) gene—rs3813867. This polymorphism was associated with oral and gastric cancer [64,65]. It might be a result of the increased production of free oxygen radicals during the metabolism of some xenobiotics in reactions catalyzed by cytochrome CYP2E1 [63].
Cytochrome P450 2E1 has also been examined in numerous studies on liver diseases [66,67,68], the metabolism of xenobiotics [69,70,71], or the side effects of various drugs, including those used to treat tuberculosis [72,73]. Within the described polymorphism, the presence of two alleles has been demonstrated, i.e., the c1 wild-type allele (G allele), which determines the lower enzymatic activity of CYP2E1 [41,74]. The second allele is the C2 allele (C allele), the presence of which is associated with a greater amount of CYP2E1 enzyme and thus a greater ability to metabolize xenobiotics, including ethanol [63]. Studies suggest that carrying the C2 allele is associated with increased alcohol consumption [44,75]. This is supported by research conducted by Konishi et al., who showed that men of Mexican-American origin who carried the C2 allele had a higher risk of alcohol dependence [76]. It is worth mentioning, in the context of the role of this polymorphism—which contributes to more toxic metabolites of alcohol—that the presence of this polymorphism (C2 allele) is associated with a greater risk of alcoholic cirrhosis [77]. It is possible that CYP2E1 polymorphisms may be involved in the pathogenesis of FASD [47]. This claim seems to be supported by the fact that in addition to the occurrence of this enzyme in the maternal liver, it is also found in the placenta, fetal liver, and fetal brain [78]. Therefore, it can be potentially expected that factors increasing CYP2E1 activity, such as the polymorphism rs3813867, may enhance oxidative stress through increased metabolism of ethyl alcohol, thus contributing to the development of FASD [18,79,80,81]. In addition, Lee et al. showed in an experimental model using human hepatocytes that placental human chorionic somatomammotropin (hCS) leads to CYP2E1 enzyme induction [82]. Concluding from that study, as well as from the fact that alcohol is also an inducer of CYP2E1, in the mother who consumes alcohol during pregnancy, the induction of CYP2E1 is more intense [68]. As polymorphism rs3813867 investigated in our study was previously associated with increased CYP2E1 hepatic content, one could expect that the combination of the presence of the C2 allele and alcohol-induced induction of CYP2E1 activity could be associated with an increased risk of FASD by intensifying the pathogenic process. This would be similar to adults, where the increased level of this enzyme associated with the presence of the C2 allele contributes to a higher risk of liver cirrhosis.
The results of the current research showed no association between the presence of the C2 allele and the risk of FAS (p = 0.262) or p-FAS (p = 0.678) in children exposed to high levels of fetal alcohol exposure (Supplementary Tables S1 and S2). Mothers’ genotypes also did not influence the risk of FAS and pFAS, p = 0.839 and p = 0.608, respectively.
Statistical analyses did not show any significant results for combined groups of PFC and FC children and mothers of PFC and FC, p = 0.475 and p = 0.724, respectively (Table 2 and Table 3). However, although the association was not confirmed, the potential importance of the studied polymorphism in the pathogenesis of FASD cannot be excluded, as the results might have been affected by the low allele frequency of this allele in the population. The C2 allele (corresponding to cytosine) constituted only 2.13% of the alleles in FC mothers, 1.22% in PFC mothers, and 2.10% in NFC mothers, whereas in children it was 2.13% (FAS), 4.76% (p-FAS), and 3.75% (non-FASD). In our study, none of the mothers or children, regardless of whether they had FAS, p-FAS, or non-FASD, were found to be homozygous for the c2 allele. Studies on another or bigger population may potentially yield different results consistent with theoretical considerations of the role of this polymorphism in the pathogenesis of FASD [45].
In summary, future studies may aim to study a more genetically diverse population, investigate other polymorphisms affecting alcohol metabolism, consider other risk factors, e.g., environmental, and relate these to the relevant genotypes.
The limitation of the present study is the low genetic diversity of the study population and the lack of consideration of other factors influencing the development of FASD, e.g., maternal comorbidities, body weight, maternal age, and the drinking pattern during pregnancy.

5. Conclusions

The results presented in this study do not support the hypothesis that SNPs within the ADH1B (rs1229984), ADH1B (rs1789891), and CYP2E1 (rs3813867) genes have an effect on the risk of FAS and its degree (FAS or pFAS). The risk of FAS was not influenced by either maternal genotype or the child’s genotype. The strength of this study was a large group of subjects with confirmed hPE. The weakness, on the other hand, was the low genetic diversity of the study population. To the authors’ knowledge, this is the first study of polymorphisms of the ADH1B/1C (rs1789891) and CYP2E1 (rs3813867) genes in the context of FASD that has attempted to experimentally associate the risk of FASD-related disorders with these polymorphisms.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/genes14071392/s1, Questionnaire developed by Wolańczyk and Kołakowski on the basis of DSM-IV Rating Scale (RS) and ICD-10 criteria; Supplementary Table S1. Genotypes and allele in FC and NFC children in ADH1B rs1229984, rs1789891, and CYP2E1 rs3813867; Supplementary Table S2 Genotypes and allele in PFC and NFC children in ADH1B rs1229984, rs1789891, and CYP2E1 rs3813867; Supplementary Table S3. Genotypes and allele in FC and NFC mothers in ADH1B rs1229984, rs1789891, and CYP2E1 rs3813867; Supplementary Table S4. Genotypes and allele in PFC and NFC mothers in ADH1B rs1229984, rs1789891, and CYP2E1 rs3813867.

Author Contributions

Conceptualization, M.A.B. and A.K.; methodology, D.M.; software, D.M.; validation, D.M. and M.K.; formal analysis, M.K.; investigation, B.B. and A.K.; resources, B.B.; data curation, D.M. and M.K.; writing—original draft preparation, A.K.; writing—review and editing, M.A.B.; visualization, D.M.; supervision, M.A.B.; project administration, A.K.; funding acquisition, M.A.B. All authors have read and agreed to the published version of the manuscript.

Funding

This project was financed by the program of the Minister of Science and Higher Education in Poland under the name “Regional Initiative of Excellence” in 2019–2022, project number 002/RID/2018/19, amount of financing 12,000,000 PLN.

Institutional Review Board Statement

This study was approved by the Ethics Committee of Pomeranian Medical University, Szczecin, Poland (KB-0012/95/15).

Informed Consent Statement

Informed consent was obtained from all subjects involved in this study.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Shastry, B.S. SNPs: Impact on Gene Function and Phenotype. Methods Mol. Biol. 2009, 578, 3–22. [Google Scholar] [CrossRef] [PubMed]
  2. Sripichai, O.; Fucharoen, S. Genetic Polymorphisms and Implications for Human Diseases. J. Med. Assoc. Thail. 2007, 90, 394–398. [Google Scholar]
  3. Eberhart, J.K.; Parnell, S.E. The Genetics of Fetal Alcohol Spectrum Disorders. Alcohol. Clin. Exp. Res. 2016, 40, 1154–1165. [Google Scholar] [CrossRef] [Green Version]
  4. Beaty, T.H.; Ruczinski, I.; Murray, J.C.; Marazita, M.L.; Munger, R.G.; Hetmanski, J.B.; Murray, T.; Redett, R.J.; Fallin, M.D.; Liang, K.Y.; et al. Evidence for gene-environment interaction in a genome wide study of nonsyndromic cleft palate. Genet. Epidemiol. 2011, 35, 469–478. [Google Scholar] [CrossRef] [PubMed]
  5. Williams, J.F.; Smith, V.C.; The Committee on Substance Abuse. Fetal Alcohol Spectrum Disorders. Pediatrics 2015, 136, e1395–e1406. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Popova, S.; Lange, S.; Probst, C.; Gmel, G.; Rehm, J. Estimation of national, regional, and global prevalence of alcohol use during pregnancy and fetal alcohol syndrome: A systematic review and meta-analysis. Lancet Glob. Health 2017, 5, e290–e299. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Lange, S.; Probst, C.; Gmel, G.; Rehm, J.; Burd, L.; Popova, S. Global Prevalence of Fetal Alcohol Spectrum Disorder among Children and Youth: A Systematic Review and Meta-analysis. JAMA Pediatr. 2017, 171, 948–956. [Google Scholar] [CrossRef]
  8. Popova, S.; Lange, S.; Shield, K.; Mihic, A.; Chudley, A.E.; Mukherjee, R.A.S.; Bekmuradov, D.; Rehm, J. Comorbidity of fetal alcohol spectrum disorder: A systematic review and meta-analysis. Lancet 2016, 387, 978–987. [Google Scholar] [CrossRef] [PubMed]
  9. Ornoy, A. Embryonic oxidative stress as a mechanism of teratogenesis with special emphasis on diabetic embryopathy. Reprod. Toxicol. 2007, 24, 31–41. [Google Scholar] [CrossRef] [PubMed]
  10. Popova, S.; Dozet, D.; Shield, K.; Rehm, J.; Burd, L. Alcohol’s Impact on the Fetus. Nutrients 2021, 13, 3452. [Google Scholar] [CrossRef]
  11. Wozniak, J.R.; Riley, E.P.; Charness, M.E. Clinical presentation, diagnosis, and management of fetal alcohol spectrum disorder. Lancet Neurol. 2019, 18, 760–770. [Google Scholar] [CrossRef] [PubMed]
  12. Burd, L. Fetal alcohol spectrum disorder: Complexity from comorbidity. Lancet 2016, 387, 926–927. [Google Scholar] [CrossRef] [PubMed]
  13. Green, R.F.; Stoler, J.M. Alcohol dehydrogenase 1B genotype and fetal alcohol syndrome: A HuGE minireview. Am. J. Obstet. Gynecol. 2007, 197, 12–25. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. May, P.A.; Gossage, J.P. Maternal risk factors for fetal alcohol spectrum disorders: Not as simple as it might seem. Alcohol Res. Health 2011, 34, 15–26. [Google Scholar]
  15. Oei, J.L. Alcohol use in pregnancy and its impact on the mother and child. Addiction 2020, 115, 2148–2163. [Google Scholar] [CrossRef]
  16. Sambo, D.; Goldman, D. Genetic Influences on Fetal Alcohol Spectrum Disorder. Genes 2023, 14, 195. [Google Scholar] [CrossRef]
  17. Burd, L.; Blair, J.; Dropps, K. Prenatal alcohol exposure, blood alcohol concentrations and alcohol elimination rates for the mother, fetus and newborn. J. Perinatol. 2012, 32, 652–659. [Google Scholar] [CrossRef] [Green Version]
  18. Gemma, S.; Vichi, S.; Testai, E. Metabolic and genetic factors contributing to alcohol induced effects and fetal alcohol syndrome. Neurosci. Biobehav. Rev. 2007, 31, 221–229. [Google Scholar] [CrossRef]
  19. Edenberg, H.J. The genetics of alcohol metabolism: Role of alcohol dehydrogenase and aldehyde dehydrogenase variants. Alcohol Res. Health 2007, 30, 5–13. [Google Scholar]
  20. Cederbaum, A.I. Alcohol metabolism. Clin. Liver Dis. 2012, 16, 667–685. [Google Scholar] [CrossRef] [Green Version]
  21. Le Daré, B.; Lagente, V.; Gicquel, T. Ethanol and its metabolites: Update on toxicity, benefits, and focus on immunomodulatory effects. Drug Metab. Rev. 2019, 51, 545–561. [Google Scholar] [CrossRef]
  22. Warren, K.R.; Li, T.K. Genetic polymorphisms: Impact on the risk of fetal alcohol spectrum disorders. Birth Defects Res. A Clin. Mol. Teratol. 2005, 73, 195–203. [Google Scholar] [CrossRef]
  23. Sultatos, L.G.; Pastino, G.M.; Rosenfeld, C.A.; Flynn, E.J. Incorporation of the genetic control of alcohol dehydrogenase into a physiologically based pharmacokinetic model for ethanol in humans. Toxicol. Sci. 2004, 78, 20–31. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Niederhut, M.S.; Gibbons, B.J.; Perez-Miller, S.; Hurley, T.D. Three-dimensional structures of the three human class I alcohol dehydrogenases. Protein Sci. 2001, 10, 697–706. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Yin, S.J.; Bosron, W.F.; Magnes, L.J.; Li, T.K. Human liver alcohol dehydrogenase: Purification and kinetic characterization of the beta 2 beta 2, beta 2 beta 1, alpha beta 2, and beta 2 gamma 1 "Oriental" isoenzymes. Biochemistry 1984, 23, 5847–5853. [Google Scholar] [CrossRef] [PubMed]
  26. Bierut, L.J.; Goate, A.M.; Breslau, N.; Johnson, E.O.; Bertelsen, S.; Fox, L.; Agrawal, A.; Bucholz, K.K.; Grucza, R.; Hesselbrock, V.; et al. ADH1B is associated with alcohol dependence and alcohol consumption in populations of European and African ancestry. Mol. Psychiatry 2012, 17, 445–450. [Google Scholar] [CrossRef] [Green Version]
  27. Muramatsu, T.; Wang, Z.C.; Fang, Y.R.; Hu, K.B.; Yan, H.; Yamada, K.; Higuchi, S.; Harada, S.; Kono, H. Alcohol and aldehyde dehydrogenase genotypes and drinking behavior of Chinese living in Shanghai. Hum. Genet. 1995, 96, 151–154. [Google Scholar] [CrossRef]
  28. Way, M.; McQuillin, A.; Saini, J.; Ruparelia, K.; Lydall, G.J.; Guerrini, I.; Ball, D.; Smith, I.; Quadri, G.; Thomson, A.D.; et al. Genetic variants in or near ADH1B and ADH1C affect susceptibility to alcohol dependence in a British and Irish population. Addict. Biol. 2015, 20, 594–604. [Google Scholar] [CrossRef]
  29. Frank, J.; Cichon, S.; Treutlein, J.; Ridinger, M.; Mattheisen, M.; Hoffmann, P.; Herms, S.; Wodarz, N.; Soyka, M.; Zill, P.; et al. Genome-wide significant association between alcohol dependence and a variant in the ADH gene cluster. Addict. Biol. 2012, 17, 171–180. [Google Scholar] [CrossRef] [Green Version]
  30. Macgregor, S.; Lind, P.A.; Bucholz, K.K.; Hansell, N.K.; Madden, P.A.; Richter, M.M.; Montgomery, G.W.; Martin, N.G.; Heath, A.C.; Whitfield, J.B. Associations of ADH and ALDH2 gene variation with self report alcohol reactions, consumption and dependence: An integrated analysis. Hum. Mol. Genet. 2009, 18, 580–593. [Google Scholar] [CrossRef] [Green Version]
  31. Lee, S.L.; Chau, G.Y.; Yao, C.T.; Wu, C.W.; Yin, S.J. Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: Significance of first-pass metabolism. Alcohol. Clin. Exp. Res. 2006, 30, 1132–1142. [Google Scholar] [CrossRef]
  32. Höög, J.O.; Hedén, L.O.; Larsson, K.; Jörnvall, H.; von Bahr-Lindström, H. The gamma 1 and gamma 2 subunits of human liver alcohol dehydrogenase. cDNA structures, two amino acid replacements, and compatibility with changes in the enzymatic properties. Eur. J. Biochem. 1986, 159, 215–218. [Google Scholar] [CrossRef]
  33. Osier, M.; Pakstis, A.J.; Kidd, J.R.; Lee, J.-F.; Yin, S.-J.; Ko, H.-C.; Edenberg, H.J.; Lu, R.-B.; Kidd, K.K. Linkage disequilibrium at the ADH2 and ADH3 loci and risk of alcoholism. Am. J. Hum. Genet. 1999, 64, 1147–1157. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Nakamura, K.; Iwahashi, K.; Matsuo, Y.; Miyatake, R.; Ichikawa, Y.; Suwaki, H. Characteristics of Japanese alcoholics with the atypical aldehyde dehydrogenase 2*2. I. A comparison of the genotypes of ALDH2, ADH2, ADH3, and cytochrome P-4502E1 between alcoholics and nonalcoholics. Alcohol Clin. Exp. Res. 1996, 20, 52–55. [Google Scholar] [CrossRef]
  35. Shen, Y.C.; Fan, J.H.; Edenberg, H.J.; Li, T.K.; Cui, Y.H.; Wang, Y.F.; Tian, C.H.; Zhou, C.F.; Zhou, R.L.; Wang, J.; et al. Polymorphism of ADH and ALDH genes among four ethnic groups in China and effects upon the risk for alcoholism. Alcohol Clin. Exp. Res. 1997, 21, 1272–1277. [Google Scholar] [CrossRef] [PubMed]
  36. Bach, P.; Zois, E.; Vollstädt-Klein, S.; Kirsch, M.; Hoffmann, S.; Jorde, A.; Frank, J.; Charlet, K.; Treutlein, J.; Beck, A.; et al. Association of the alcohol dehydrogenase gene polymorphism rs1789891 with gray matter brain volume, alcohol consumption, alcohol craving and relapse risk. Addict. Biol. 2019, 24, 110–120. [Google Scholar] [CrossRef] [Green Version]
  37. Oniszczenko, W.; Rybakowski, J.K.; Dragan, W.Ł.; Grzywacz, A.; Samochowiec, J. The ADH gene cluster SNP rs1789891 and temperamental dimensions in patients with alcohol dependence and affective disorders. Scand. J. Psychol. 2015, 56, 420–427. [Google Scholar] [CrossRef]
  38. Rendic, S.; Guengerich, F.P. Survey of Human Oxidoreductases and Cytochrome P450 Enzymes Involved in the Metabolism of Xenobiotic and Natural Chemicals. Chem. Res. Toxicol. 2015, 28, 38–42. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  39. Sharzehan, M.A.K.; Sito, H.; Abdullah, N.; Alexiou, A.; Papadakis, M.; Jamal, R.; Tan, S.C. Association between CYP2E1 polymorphisms and colorectal cancer risk: A systematic review and meta-analysis. Sci. Rep. 2022, 12, 20149. [Google Scholar] [CrossRef]
  40. Li, Y.; Marion, M.J.; Zipprich, J.; Santella, R.M.; Freyer, G.; Brandt-Rauf, P.W. Gene-environment interactions between DNA repair polymorphisms and exposure to the carcinogen vinyl chloride. Biomarkers 2009, 14, 148–155. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  41. Hayashi, S.; Watanabe, J.; Kawajiri, K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J. Biochem. 1991, 110, 559–565. [Google Scholar] [CrossRef] [Green Version]
  42. Koop, D.R.; Nordblom, G.D.; Coon, M.J. Immunochemical evidence for a role of cytochrome P-450 in liver microsomal ethanol oxidation. Arch. Biochem. Biophys. 1984, 235, 228–238. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Jin, M.; Ande, A.; Kumar, A.; Kumar, S. Regulation of cytochrome P450 2e1 expression by ethanol: Role of oxidative stress-mediated pkc/jnk/sp1 pathway. Cell Death Dis. 2013, 4, e554. [Google Scholar] [CrossRef] [Green Version]
  44. Sun, F.; Tsuritani, I.; Yamada, Y. Contribution of genetic polymorphisms in ethanol-metabolizing enzymes to problem drinking behavior in middle-aged Japanese men. Behav. Genet. 2002, 32, 229–236. [Google Scholar] [CrossRef] [PubMed]
  45. Ehrhart, F.; Roozen, S.; Verbeek, J.; Koek, G.; Kok, G.; Van Kranen, H.; Evelo, C.; Curfs, L.M.G. Review and gap analysis: Molecular pathways leading to fetal alcohol spectrum disorders. Mol. Psychiatry 2019, 24, 10–17. [Google Scholar] [CrossRef] [PubMed]
  46. Ramsay, M. Genetic and epigenetic insights into fetal alcohol spectrum disorders. Genome Med. 2010, 2, 27. [Google Scholar] [CrossRef] [Green Version]
  47. Pikkarainen, P.H. Metabolism of ethanol and acetaldehyde in perfused human fetal liver. Life Sci. II 1971, 10, 1359–1364. [Google Scholar] [CrossRef]
  48. Lieber, C.S. Microsomal ethanol-oxidizing system. Enzyme 1987, 37, 45–56. [Google Scholar] [CrossRef]
  49. Zelner, I.; Koren, G. Pharmacokinetics of ethanol in the maternal-fetal unit. J. Popul. Ther. Clin. Pharmacol. 2013, 20, e259–e265. [Google Scholar]
  50. Hakkola, J.; Pelkonen, O.; Pasanen, M.; Raunio, H. Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: Role in intrauterine toxicity. Crit. Rev. Toxicol. 1998, 28, 35–72. [Google Scholar] [CrossRef]
  51. Pelkonen, O. Biotransformation of xenobiotics in the fetus. Pharmacol. Ther. 1980, 10, 261–281. [Google Scholar] [CrossRef] [PubMed]
  52. Carpenter, S.P.; Lasker, J.M.; Raucy, J.L. Expression, induction, and catalytic activity of the ethanol-inducible cytochrome P450 (CYP2E1) in human fetal liver and hepatocytes. Mol. Pharmacol. 1996, 49, 260–268. [Google Scholar] [PubMed]
  53. Edenberg, H.J.; McClintick, J.N. Alcohol Dehydrogenases, Aldehyde Dehydrogenases, and Alcohol Use Disorders: A Critical Review. Alcohol Clin. Exp. Res. 2018, 42, 2281–2297. [Google Scholar] [CrossRef]
  54. Edenberg, H.J.; Xuei, X.; Chen, H.J.; Tian, H.; Wetherill, L.F.; Dick, D.M.; Almasy, L.; Bierut, L.; Bucholz, K.K.; Goate, A.; et al. Association of alcohol dehydrogenase genes with alcohol dependence: A comprehensive analysis. Hum. Mol. Genet. 2006, 15, 1539–1549. [Google Scholar] [CrossRef] [Green Version]
  55. Thomasson, H.R.; Edenberg, H.J.; Crabb, D.W.; Mai, X.L.; Jerome, R.E.; Li, T.K.; Wang, S.P.; Lin, Y.T.; Lu, R.B.; Yin, S.J. Alcohol and aldehyde dehydrogenase genotypes and alcoholism in Chinese men. Am. J. Hum. Genet. 1991, 48, 677–681. [Google Scholar]
  56. Li, D.; Zhao, H.; Gelernter, J. Strong association of the alcohol dehydrogenase 1B gene (ADH1B) with alcohol dependence and alcohol-induced medical diseases. Biol. Psychiatry 2011, 70, 504–512. [Google Scholar] [CrossRef] [Green Version]
  57. Zintzaras, E.; Stefanidis, I.; Santos, M.; Vidal, F. Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? Hepatology 2006, 43, 352–361. [Google Scholar] [CrossRef] [PubMed]
  58. Park, B.L.; Kim, J.W.; Cheong, H.S.; Kim, L.H.; Lee, B.C.; Seo, C.; Kang, T.-C.; Nam, Y.-W.; Kim, G.-B.; Shin, H.D.; et al. Extended genetic effects of ADH cluster genes on the risk of alcohol dependence: From GWAS to replication. Hum. Genet. 2013, 132, 657–668. [Google Scholar] [CrossRef]
  59. Luczak, S.E.; Glatt, S.J.; Wall, T.L. Meta-analyses of ALDH2 and ADH1B with alcohol dependence in Asians. Psychol. Bull. 2006, 132, 607–621. [Google Scholar] [CrossRef]
  60. Viljoen, D.L.; Carr, L.G.; Foroud, T.M.; Brooke, L.; Ramsay, M.; Li, T.K. Alcohol dehydrogenase-2*2 allele is associated with decreased prevalence of fetal alcohol syndrome in the mixed-ancestry population of the Western Cape Province, South Africa. Alcohol Clin. Exp. Res. 2001, 25, 1719–1722. [Google Scholar] [CrossRef]
  61. Zuccolo, L.; Fitz-Simon, N.; Gray, R.; Ring, S.M.; Sayal, K.; Smith, G.D.; Lewis, S.J. A non-synonymous variant in ADH1B is strongly associated with prenatal alcohol use in a European sample of pregnant women. Hum. Mol. Genet. 2009, 18, 4457–4466. [Google Scholar] [CrossRef] [Green Version]
  62. Yun, Y.P.; Casazza, J.P.; Sohn, D.H.; Veech, R.L.; Song, B.J. Pretranslational activation of cytochrome P450IIE during ketosis induced by a high fat diet. Mol. Pharmacol. 1992, 41, 474–479. [Google Scholar] [PubMed]
  63. Neafsey, P.; Ginsberg, G.; Hattis, D.; Johns, D.O.; Guyton, K.Z.; Sonawane, B. Genetic polymorphism in CYP2E1: Population distribution of CYP2E1 activity. J. Toxicol. Environ. Health B Crit. Rev. 2009, 12, 362–388. [Google Scholar] [CrossRef] [PubMed]
  64. Guo, Y.; Zhou, S.; Liu, F.; Zhang, B. CYP2E1 RsaI/PstI polymorphisms contributed to oral cancer susceptibility: A meta-analysis. Int. J. Clin. Exp. Pathol. 2015, 8, 14685–14692. [Google Scholar]
  65. Wang, R.Y.; Chen, X.W.; Zhang, W.W.; Jiang, F.; Liu, M.Q.; Shen, X.B. CYP2E1 changes the biological function of gastric cancer cells via the PI3K/Akt/mTOR signaling pathway. Mol. Med. Rep. 2020, 21, 842–850. [Google Scholar] [CrossRef] [Green Version]
  66. Neuman, M.G.; Malnick, S.; Maor, Y.; Nanau, R.M.; Melzer, E.; Ferenci, P.; Seitz, H.K.; Mueller, S.; Mell, H.; Samuel, D.; et al. Alcoholic liver disease: Clinical and translational research. Exp. Mol. Pathol. 2015, 99, 596–610. [Google Scholar] [CrossRef]
  67. Guengerich, F.P. Cytochrome P450 2E1 and its roles in disease. Chem. Biol. Interact. 2020, 322, 109056. [Google Scholar] [CrossRef]
  68. Diesinger, T.; Buko, V.; Lautwein, A.; Dvorsky, R.; Belonovskaya, E.; Lukivskaya, O.; Naruta, E.; Kirko, S.; Andreev, V.; Buckert, D.; et al. Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis. PLoS ONE 2020, 15, e0235990. [Google Scholar] [CrossRef] [PubMed]
  69. Chen, J.; Jiang, S.; Wang, J.; Renukuntla, J.; Sirimulla, S.; Chen, J. A comprehensive review of cytochrome P450 2E1 for xenobiotic metabolism. Drug Metab. Rev. 2019, 51, 178–195. [Google Scholar] [CrossRef]
  70. Lucas, D.; Ferrara, R.; Gonzales, E.; Albores, A.; Manno, M.; Berthou, F. Cytochrome CYP2E1 phenotyping and genotyping in the evaluation of health risks from exposure to polluted environments. Toxicol. Lett. 2001, 124, 71–81. [Google Scholar] [CrossRef]
  71. Bolt, H.M.; Roos, P.H.; Thier, R. The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: Consequences for occupational and environmental medicine. Int. Arch. Occup. Environ. Health 2003, 76, 174–185. [Google Scholar] [CrossRef] [PubMed]
  72. Roy, P.D.; Majumder, M.; Roy, B. Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Pharmacogenomics 2008, 9, 311–321. [Google Scholar] [CrossRef] [PubMed]
  73. Perwitasari, D.A.; Atthobari, J.; Wilffert, B. Pharmacogenetics of isoniazid-induced hepatotoxicity. Drug Metab. Rev. 2015, 47, 222–228. [Google Scholar] [CrossRef] [Green Version]
  74. Tsutsumi, M.; Wang, J.S.; Takase, S.; Takada, A. Hepatic messenger RNA contents of cytochrome P4502E1 in patients with different P4502E1 genotypes. Alcohol Alcohol. Suppl. 1994, 29, 29–32. [Google Scholar] [CrossRef] [PubMed]
  75. Tanaka, H.; Ikai, E.; Yamada, Y. Genetic polymorphisms in alcohol metabolizing enzymes as related to sensitivity to alcohol-induced health effects. Environ. Health Prev. Med. 1997, 1, 193–200. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Konishi, T.; Calvillo, M.; Leng, A.S.; Feng, J.; Lee, T.; Lee, H.; Smith, J.L.; Sial, S.H.; Berman, N.; French, S.; et al. The ADH3*2 and CYP2E1 c2 alleles increase the risk of alcoholism in Mexican American men. Exp. Mol. Pathol. 2003, 74, 183–189. [Google Scholar] [CrossRef]
  77. Cichoz-Lach, H.; Partycka, J.; Nesina, I.; Celiński, K.; Słomka, M. The influence of genetic polymorphism of CYP2E1 on the development of alcohol liver cirrhosis. Wiad Lek. 2006, 59, 757–761. [Google Scholar]
  78. Rasheed, A.; Hines, R.N.; McCarver-May, D.G. Variation in induction of human placental CYP2E1: Possible role in susceptibility to fetal alcohol syndrome? Toxicol. Appl. Pharmacol. 1997, 144, 396–400. [Google Scholar] [CrossRef]
  79. Brzezinski, M.R.; Boutelet-Bochan, H.; Person, R.E.; Fantel, A.G.; Juchau, M.R. Catalytic activity and quantitation of cytochrome P-450 2E1 in prenatal human brain. J. Pharmacol. Exp. Ther. 1999, 289, 1648–1653. [Google Scholar]
  80. Boutelet-Bochan, H.; Huang, Y.; Juchau, M.R. Expression of CYP2E1 during embryogenesis and fetogenesis in human cephalic tissues: Implications for the fetal alcohol syndrome. Biochem. Biophys. Res. Commun. 1997, 238, 443–447. [Google Scholar] [CrossRef]
  81. García-Suástegui, W.A.; Ramos-Chávez, L.A.; Rubio-Osornio, M.; Calvillo-Velasco, M.; Atzin-Méndez, J.A.; Guevara, J.; Silva-Adaya, D. The role of CYP2E1 in the drug metabolism or bioactivation in the brain. Oxid. Med. Cell. Longev. 2017, 2017, 4680732. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  82. Lee, J.K.; Chung, H.J.; Fischer, L.; Fischer, J.; Gonzalez, F.J.; Jeong, H. Human placental lactogen induces CYP2E1 expression via PI 3-kinase pathway in female human hepatocytes. Drug Metab. Dispos. 2014, 42, 492–499. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Table
Table 1. Demographic data of patients (mothers and children) enrolled in the study.
Table 1. Demographic data of patients (mothers and children) enrolled in the study.
hPAE Children GroupnAge [Years]Female Sex [n]Female Sex [%]
total3038.94 ± 4.9021370.30%
FC1418.96 ± 5.078459.57%
PFC428.60 ± 3.873788.07%
NFC1209.03 ± 5.069276.67%
Mothers GroupnAge [Years]
total25132.77 ± 5.93
total (hPAE groups) *
FC13533.36 ± 5.97
PFC4133.15 ± 4.53
NFC11932.63 ± 5.91
hPAE—high prenatal alcohol exposure, FAS children—FC, partial FAS children—PFC, non-morphological FAS children—NFC; * including mothers with more than one additional child.
Table
Table 2. Genotypes and alleles in FC + PFC and NFC mothers in ADH1B rs1229984, rs1789891, and CYP2E1 rs3813867.
Table 2. Genotypes and alleles in FC + PFC and NFC mothers in ADH1B rs1229984, rs1789891, and CYP2E1 rs3813867.
FC + PFC Mothers (n = 176)NFC Mothers (n = 119)p a p bOR (95% CI)
n%n%
ADH1B rs1229984
genotype
GG15789.21%10789.92% TT + CT vs. CC1.001.08 (0.50–2.32)
GA1910.79%119.24%0.438TT vs. CT + CC0.40-
AA00.00%10.84% TT vs. CC0.41-
CT vs. CC0.851.18 (0.54–2.57)
TT vs. CT0.39-
ADH1B rs1229984
allele
G33394.60%22594.54%
A195.40%135.46% T vs. C1.000.99 (0.48–2.04)
ADH1B rs1789891
genotype
CC10861.36%8067.23% AA + CA vs. CC0.331.29 (0.79–2.11)
CA5832.96%3327.73%0.587AA vs. CA + CC1.001.14 (0.40–3.21)
AA105.68%65.04% AA vs. CC0.801.24 (0.43–3.54)
CA vs. CC0.361.30 (0.78–2.18)
AA vs. CA1.000.95 (0.32–2.85)
ADH1B rs1789891
allele
C27477.84%19381.09%
A7822.16%4518.91% A vs. C0.351.22 (0.81–1.84)
CYP2E1 rs3813867
genotype
GG17096.59%11495.80% CC + GC vs. GG0.760.81 (0.24–2.70)
GC63.41%54.20%0.724CC vs. GC + GG1.00-
CC00.00%00.00% CC vs. GG1.00-
GC vs. GG0.760.81 (0.24–2.70)
CC vs. GC1.00-
CYP2E1 rs3813867
allele
G34698.30%23397.90%
C61.70%52.10% C vs. G0.760.81 (0.25–2.68)
a χ2 test. b Fisher’s exact test.
Table
Table 3. Genotypes and alleles in FC + PFC and NFC children in ADH1B rs1229984, rs1789891, and CYP2E1 rs3813867.
Table 3. Genotypes and alleles in FC + PFC and NFC children in ADH1B rs1229984, rs1789891, and CYP2E1 rs3813867.
FC + PFC (n = 183)NFC (n = 120)p a p bOR (95% CI)
n%n%
ADH1B rs1229984
genotype
GG17293.99%11091.67% TT + CT vs. CC0.490.70 (0.29–1.71)
GA116.01%108.33%0.436TT vs. CT + CC1.00-
AA00.00%00.00% TT vs. CC1.00-
CT vs. CC0.490.70 (0.29–1.71)
TT vs. CT1.00-
ADH1B rs1229984
allele
G35597.00%23095.83%
A113.00%104.17% T vs. C0.500.71 (0.30–1.71)
ADH1B rs1789891
genotype
CC12266.67%7865.00% AA + CA vs. CC0.810.93 (0.57–1.51)
CA5429.51%3730.83%0.954AA vs. CA + CC1.000.92 (0.28–2.95)
AA73.82%54.17% AA vs. CC1.000.90 (0.27–2.92)
CA vs. CC0.800.93 (0.56–1.55)
AA vs. CA1.000.96 (0.28–3.25)
ADH1B rs1789891
allele
C29881.42%19380.42%
A6818.58%4719.58% A vs. C0.750.94 (0.62–1.42)
CYP2E1 rs3813867
genotype
GG17394.54%11192.50% CC + GC vs. GG0.480.71 (0.28–1.81)
GC105.46%97.50%0.475CC vs. GC + GG1.00-
CC00.00%00.00% CC vs. GG1.00-
GC vs. GG0.480.71 (0.28–1.81)
CC vs. GC1.00-
CYP2E1 rs3813867
allele
G35697.27%23196.25%
C102.73%93.75% C vs. G0.490.72 (0.29–1.80)
a χ2 test. b Fisher’s exact test.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kukowka, A.; Brzuchalski, B.; Kurzawski, M.; Malinowski, D.; Białecka, M.A. ADH1B, ADH1B/C and CYP2E1 Gene Polymorphism and the Risk of Fetal Alcohol Spectrum Disorder. Genes 2023, 14, 1392. https://doi.org/10.3390/genes14071392

AMA Style

Kukowka A, Brzuchalski B, Kurzawski M, Malinowski D, Białecka MA. ADH1B, ADH1B/C and CYP2E1 Gene Polymorphism and the Risk of Fetal Alcohol Spectrum Disorder. Genes. 2023; 14(7):1392. https://doi.org/10.3390/genes14071392

Chicago/Turabian Style

Kukowka, Arnold, Bogusław Brzuchalski, Mateusz Kurzawski, Damian Malinowski, and Monika Anna Białecka. 2023. "ADH1B, ADH1B/C and CYP2E1 Gene Polymorphism and the Risk of Fetal Alcohol Spectrum Disorder" Genes 14, no. 7: 1392. https://doi.org/10.3390/genes14071392

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop